Ytiliga Private Limited

Ytiliga is a dynamic and rapidly evolving pharmaceutical company founded on 09 May 2016. Our journey began with a focus on gynaecology, and we have since expanded to include a diverse range of specialities, reflecting our commitment to addressing the evolving needs of the healthcare industry. Divisions and Product Ranges Gynaecology Range: Our initial product line focused on women's health, setting the foundation for our reputation in quality healthcare solutions. UroTron™ (2018): Our urology division addresses various urological conditions with innovative products. NephroTron™ (2020): Dedicated to advanced treatments for kidney-related conditions. UroOncology (2022): Specialized treatments for cancers of the urinary system. AndroXprts™ (2024): Targeting the unaddressed andrology market with innovative research-backed products. CNStron™ (2024): Advanced neurological treatments for comprehensive healthcare solutions. Research and Innovation Research and innovation are the cornerstones of Ytiliga. Our name, derived from "agility" and transformed into "Ytiliga," reflects our founding principle of being agile and adaptable. This core value drives our commitment to excellence, innovation, and responsiveness to market needs. Achievements and Recognition Ytiliga was recognized as one of the 20 Best Lifesciences Startups in 2018, a testament to our aggressive brand building and impactful presence in the industry. We hold around 70 trademarks and numerous patent applications under our IPR division, underscoring our commitment to innovation. Quality and Vision Our motto,"Driven by Quality, Defined by Results," reflects our unwavering dedication to excellence. We believe in crafting even the tiniest details to perfection and take great pride in our unparalleled quality. Our vision is to establish Ytiliga as an institution of research, synonymous with the best quality worldwide, providing world-class healthcare solutions driven by agility and defined by results.